US FDA panel backs Replimune skin cancer drug study data
30/07/2026 22:02
US FDA panel backs Replimune skin cancer drug study data July 30 (Reuters) - A panel of outside advisers to the FDA voted to back results from a trial studying Replimune's REPL.O drug for a type of skin cancer in a meeting on Thursday.
(Reporting by Puyaan Singh in Bengaluru; Editing by Shailesh Kuber)
Recent news on Replimune
See all newsTrump picks White House adviser Heidi Overton to run FDA, source says (updated)
Brief: Replimune Group, Inc. Files For Mixed Shelf Size Not Disclosed
Brief: Replimune Reports Fiscal First Quarter 2027 Financial Results And Provides Corporate Update
Replimune Q1 net loss narrows as expenses decline
U.S. STOCKS ON THE MOVE-Microsoft, Coastal Financial, Eli Lilly